A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. - Wikidata - awgldk - TriplyDB

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

http://www.wikidata.org/entity/Q46576710

about

From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implications PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction The genetics and screening of familial hypercholesterolaemia Lipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature review PCSK9 and triglyceride-rich lipoprotein metabolism Profile of evolocumab and its potential in the treatment of hyperlipidemia Glycaemic Effects of Non-statin Lipid-Lowering Therapies Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders PCSK9 inhibitors in the prevention of cardiovascular disease PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era Retargeting the management of hypercholesterolemia - focus on evolocumab Evolocumab PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future Nonstatin Low-Density Lipoprotein-Lowering Therapy and Cardiovascular Risk Reduction-Statement From ATVB Council PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date LDL-Cholesterol: Standards of Treatment 2016: A German Perspective.Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data.Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials.PCSK9 and Atherosclerosis - Lipids and Beyond.PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade.Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SB Familial hypercholesterolemia: developments in diagnosis and treatment The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.Nontraditional serum lipid variables and recurrent stroke risk.Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9).Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.PCSK9 antibodies for the treatment of hypercholesterolemia Familial hypercholesterolemia Identifying genetic risk variants for coronary heart disease in familial hypercholesterolemia: an extreme genetics approach.Coronary heart disease and genetic variants with low phospholipase A2 activity Atherosclerosis: cell biology and lipoproteins PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9.Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials.Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials

P2860

Q26741078-A306F99E-FBD9-4A05-86E6-84E5C671499B Q26747776-7C1BC385-D53C-4F98-BDC5-96F6A1D4D237 Q26752950-1F4A8B87-982F-40DB-AE1B-C2D9F41177F6 Q26753081-1ADB4E57-1FDB-4090-BABF-A8B6EA599C84 Q26771862-4751A94F-4D84-438C-8C73-77148E3B5572 Q26796287-1D60B8F3-5AA1-4FBA-889B-D11D50D0E140 Q27004235-4D227D79-D7A9-4272-BBAC-308E9E4257A4 Q28070152-7ACCD437-4DFB-4A9E-9513-5168C82420F6 Q28070296-02DD5780-6965-4D22-B9BC-3616957FB11C Q28071452-6362FA48-FED1-4648-9987-8DC477C84CDB Q28073656-472EF6DD-8888-49AC-BD7F-C1D3FF9B83B5 Q28077289-23363968-E761-4817-9C4F-3D06D67158D5 Q28078902-D2E34D61-37E5-4318-902B-23DA4792D0C5 Q28083595-2248B38C-8335-4A51-A895-FBC8567399FD Q28084156-B7605BC4-D116-418C-8A35-3B2D740E0AAA Q28275648-E0D5B6FF-5696-4E65-899B-CDF629BDC923 Q30234612-C52CB9A4-3C15-4FC6-ABDA-1A4701D77FF0 Q30244599-AED75A2B-668B-4FDB-A8C7-7F848DFD182D Q30248925-D01B5925-B12E-4156-9A3B-0E8791831C2F Q30833167-3B15D4CA-9108-4F9C-8CB1-212AFDDD5D9A Q33670893-ACFD6D4B-E150-4DA9-9F91-73CC1C2AAF2C Q33675963-4517E86A-8E6A-4637-9D3A-81DFC41E6E5A Q33904455-7817B8CB-6FC6-43A6-BB74-D65549E482DE Q33908782-63493830-74C7-433F-8D19-FB976B1873DC Q34106665-874C2087-859A-4281-A0AE-D886CBF1D6FC Q34355679-8E24BBBE-A328-4885-AADB-57202EC3841D Q34423344-15B4BE6C-3215-4F5C-98D4-2663C68D7245 Q34430377-DCA4C91C-A13E-4546-8284-FD529AC7B74C Q34433146-1A4EA733-C04B-4F81-B102-C3F54B4D3D42 Q34458693-BADFE24B-1E4D-416F-AA09-481EE90A3A8D Q34536594-2A4A58F9-DC22-440D-B0E5-07C11F09319C Q34774969-513F06AF-5982-4CA5-B7FE-C7EEA05E7A06 Q34971772-EECD0CD1-2C5F-43EB-B694-86F4607FE335 Q35079924-41AF9D29-68EA-478C-A25A-590904341EFA Q35116234-4E905510-40CB-4E71-84E3-05674DA320C4 Q35241610-0AB9FC7E-BEFE-4EC8-A95D-D933C894F951 Q35262593-49B501C1-A533-460D-B8E1-1517EA54FED3 Q35603530-77A22CCC-A6BA-411B-A35C-5F35EB73EA9D Q35664577-18B4F4C6-7737-4DC1-9A80-E1DB3FF25640 Q35671077-79C2D702-3CA5-4CDB-B78E-98E085593BBB

P2860

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

http://www.wikidata.org/entity/Q46576710

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

@en

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

@nl

type

label

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

@en

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

@nl

prefLabel

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

@en

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

@nl

P1433

Q46576710-FBBC474D-251D-4DA1-9309-B7B405763573

P1476

Q46576710-DFF109F4-9741-4D02-A4AC-7CA03E4D564E

P2093

Q46576710-06EB18FA-211D-44F7-AF24-58B2F6FA2E9E

Q46576710-09D31774-504F-40C0-8C47-74EA33359EE8

Q46576710-0D858112-D51C-4079-8057-E46630DD9009

Q46576710-13C0D8C9-5E8D-40E9-90E2-35A1CC24BC7F

Q46576710-1F9D5C42-0B70-4A3E-9572-8739D8E99143

Q46576710-4AAFA788-49F9-46C6-8A78-8DCCD1C6BDDD

Q46576710-779AD85D-B3E5-4069-8BEC-74F3436FFD10

Q46576710-7EB94C6C-D23F-4453-8C78-35362BE7AE76

Q46576710-8B6F2A6A-6EF4-4A7E-B79A-8EBCD92D70BF

Q46576710-A42A2E3E-99A8-4DC4-A736-8F675A401531

P304

Q46576710-4C14D6BD-73FB-4619-9049-7D679AB21887

P31

Q46576710-9C76D37D-F7FC-402B-8593-6FF11E010313

P356

Q46576710-EF358F5A-4500-4D14-B346-72A545D84544

P407

Q46576710-EEFB33C7-6136-4D72-A1AA-0A99CD067A59

P433

Q46576710-596AF8CB-C465-44D5-B95E-DFD63FC9A5FB

P478

Q46576710-9E235579-E3F2-4BCC-8821-8688327D90BB

P50

Q46576710-D8D225E5-9A10-41CB-85A3-54D4A6D7A84F

P577

Q46576710-B06C5A94-9E67-4100-B5D1-FF1CC0318C70

P698

Q46576710-A9933CEA-FCA1-49A9-B54F-9C85492610FD

P921

Q46576710-1047F32E-7537-4D2F-9625-3186065793FD

Q46576710-CE3F8C90-5936-43AD-9C96-F0ACE314CBAD

P356

P1433

The New England Journal of Medicine

P1476

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

@en

P2093

Christie M Ballantyne

http://www.w3.org/2001/XMLSchema#string

DESCARTES Investigators

http://www.w3.org/2001/XMLSchema#string

Dirk J Blom

http://www.w3.org/2001/XMLSchema#string

Eli Roth

http://www.w3.org/2001/XMLSchema#string

Evan A Stein

http://www.w3.org/2001/XMLSchema#string

Jae B Kim

http://www.w3.org/2001/XMLSchema#string

Kate Tsirtsonis

http://www.w3.org/2001/XMLSchema#string

Lesley Burgess

http://www.w3.org/2001/XMLSchema#string

Maria Laura Monsalvo

http://www.w3.org/2001/XMLSchema#string

Michael Bolognese

http://www.w3.org/2001/XMLSchema#string

P304

1809-1819

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1316222

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24678979

http://www.w3.org/2001/XMLSchema#string

P921